Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control
Charlotte Pawlyn(Royal Marsden NHS Foundation Trust), Faith E. Davies(NYU Langone Health)
Cited by 105
Related Papers
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k
The genetic architecture of multiple myeloma
|Nature reviews. Cancer|2012|919
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
|Blood|2001|905